WHO Eyes More Data on Merck’s New Covid‑19 Pill
In Geneva, the World Health Organization (WHO) announced that it needs extra info from Merck about their experimental Covid‑19 antiviral pill. They’re hoping to drop a clear guideline in the next few weeks for treating mild to moderate cases.
Key Takeaway
- WHO is actively looking for more clinical data from Merck’s trials happening overseas.
- Maria van Kerkhove, a WHO expert, said, “We’re evaluating the drug and sit‑down with Merck on Friday to peek at the latest trial outcomes.”
- She added, “We expect good news soon!”
What’s Next for Covaxin?
Meanwhile, Merck’s partner, Ridgeback Biotherapeutics, is working on molnupiravir. On another front, WHO’s assistant‑director Mariangela Simao is pushing for an emergency use decision on Bharat Biotech’s Covaxin vaccine. She plans to finalize things in a forthcoming Nov 3 meeting after requesting more data from the Indian firm.
Bottom Line
WHO keeps its finger on the pulse, gathering more evidence before giving the green light. So stay tuned – we’ll have the latest updates before you finish your coffee.
